key: cord-0727416-ojmi0ey7 authors: Rouet, Romain; Mazigi, Ohan; Walker, Gregory J.; Langley, David B.; Sobti, Meghna; Schofield, Peter; Lenthall, Helen; Jackson, Jennifer; Ubiparipovic, Stephanie; Henry, Jake Y.; Abayasingam, Arunasingam; Burnett, Deborah; Kelleher, Anthony; Brink, Robert; Bull, Rowena A.; Turville, Stuart; Stewart, Alastair G.; Goodnow, Christopher C.; Rawlinson, William D.; Christ, Daniel title: Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies date: 2020-12-15 journal: bioRxiv DOI: 10.1101/2020.12.14.422791 sha: bcc8d21c9bf53ee9096a256489449f92f3f615be doc_id: 727416 cord_uid: ojmi0ey7 Antibodies against coronavirus spike protein potently protect against infection and disease, however it remains unclear if such protection can be extended to variant coronaviruses. This is exemplified by a set of iconic and well-characterized monoclonal antibodies developed after the 2003 SARS outbreak including mAbs m396, CR3022, CR3014 and 80R, which potently neutralize SARS-CoV-1, but not SARS-CoV-2. Here we explore antibody maturation strategies to change and broaden their specificity, enabling potent binding and neutralization of SARS-CoV-2. Using targeted mutagenesis as well as light chain shuffling on phage, we identified variants with considerably increased affinity and neutralization potential. The most potent antibody, derived from the NIH-developed mAb m396, neutralized live SARS-CoV-2 virus with a half-maximal inhibitory concentration (IC50) of 160 ng/ml. Intriguingly, while many of the matured clones maintained specificity of the parental antibody, new specificities were also observed, which was further confirmed by X-ray crystallography and cryo-electron microscopy, indicating that a limited set of antibodies can give rise to variants targeting diverse epitopes. Our findings open up over 15 years of antibody development efforts against SARS-CoV-1 to the SARS-CoV-2 field and outline general principles for the maturation of antibody specificity against emerging viruses. The emergence of at least three coronaviruses (SARS-CoV-1, SARS-CoV-2 and MERS) in the human population in the last two decades has highlighted the need for rapid and sustained development of prophylactic and therapeutic modalities. Among such modalities, antibody reagents blocking the interaction of the viral spike protein with human receptor (angiotensin converting enzyme 2 (ACE2) in the case of SARS-CoV-1 and CoV-2, and dipeptidyl peptidase 4 (DPP4) in the case of MERS) are among the most promising [1] [2] [3] . Various approaches have been used to identify neutralizing antibodies, including the identification of B-cells from convalescent patients 4, 5 , the immunization of humanized transgenic mice 6 , or through the use of in vitro library display approaches against viral spike protein (or more commonly its receptor binding domain (RBD)) 7,8 . Here we employed a different approach based on the re-engineering and maturation of previously reported antibodies against SARS-CoV-1. Although such antibodies generally do not bind and neutralize SARS-CoV-2, we speculated that the relatively high level of sequence identify of the RBD of the two viruses (76% amino acid identity 9, 10 ) would allow us to shift antibody specificity through limited changes in antibody variable regions. We focused our attention on four well-characterized monoclonal antibodies (m396 11 , CR3022 12 , CR3014 13 and 80R 14 ) which bind and neutralize SARS-CoV-1 with equilibrium binding and IC50 constants in the nanomolar range. Crystal structures have been reported for m396 11 , CR3022 12 and 80R 14 in complex with RBD; these reveal binding to a diverse set of epitopes, with m396 and 80R binding to distinct, but adjacent, epitopes overlapping with the ACE2 binding site (Fig. 1a) . Although no structural information has been reported for CR3014, the antibody has been shown to block ACE2 binding 12 . In marked contrast, CR3022 binds to an epitope distant to the ACE2 binding site which is largely conserved between SARS-CoV-1 and SARS-CoV-2 15 . Unlike m396, CR3014 and 80R, CR3022 displays residual binding to SARS-CoV-2 RBD; however, it does not detectably neutralize live SARS-CoV-2 virus 15 . For the re-engineering strategy, we focused on two well-established in vitro methods for antibody affinity maturation: (I) site-directed mutagenesis of complementarity determining regions (CDR) of human variable domains 16 and (II) light chain shuffling 17 (Fig. 1B-D) . Library design based on the reported structures of m396, CR3022 and 80R in complex with RBD was used for the construction of site-directed mutagenesis repertoires, with antibody contact residues with antigen targeted for diversification. For the alternative light chain shuffling approach, a previously described highly diverse synthetic antibody library based on a single Vk1 framework was utilized 18, 19 . Both library classes were then selected for binding to SARS-CoV-2 RBD using iterative selections on biotinylated antigen (100 nM to 500 pM range). Using these approaches, we rapidly identified human antibody variants with potent affinity and neutralization potential for SARS-CoV-2. For the design of site-directed mutagenesis libraries, we utilized previously reported crystal structures of antibodies developed against SARS-CoV-1 in complex with either cognate RBD (80R -PDB ID 2ghw 20 ; m396 -PDB ID 2dd8 21 ) or SARS-CoV-2 RBD in the case of the cross-specific CR3022 antibody (PDB ID 6w41 15 ). Based on the structures, we selected contact and proximal residues in CDR regions of VH and VL, which were targeted for diversification by Kunkel mutagenesis 16 Table 1 ; all six CDR regions were targeted for CR3014 for which no structural information has been reported). Library construction was carried out in an antibody single-chain Fv (scFv) format, resulting in 6.1 x 10 8 , 2.3 x 10 7 , 3.4 x 10 7 and 5.7 x 10 7 clones for m396, CR3022, CR3014 and 80R respectively. We performed four rounds of phage display selection, using decreasing amounts of SARS-CoV-2 RBD for selection (see Methods); this resulted in enrichment of SARS-CoV-2 specific binders for the libraries (with the exception of CR3014), as indicated by polyclonal phage ELISA ( Fig. 2A) . Screening of individual clones by monoclonal soluble ELISA was performed after round 4, followed by sequencing and cloning of non-redundant variants into an IgG expression vector. After production in CHO cells, monoclonal antibodies were characterized for binding to recombinant RBD by biolayer-interferometry (BLI) and for neutralization of live SARS-CoV-2 virus in Vero E6 cells. In the case of m396, two variants (designated B10 and C4) were chosen for further characterization, with both antibody variants encoding several mutations in VH and VL Table 1 ). Both variants also potently neutralized live SARS-CoV-2 virus with IC50s of 160 ng/ml and 340 ng/ml, respectively ( Fig. 2C and Supplementary Fig. 1E ). In addition to live virus, m396-B10 also potently neutralized both SARS-CoV-1 and SARS-CoV-2 pseudoparticles (with IC50s of 2.2 and 0.3 µg/ml, respectively) ( Supplementary Fig. 1L ). The B10 variant of m396 was further selected for structural characterization by crystallography in a Fab format, both in isolation and in complex with SARS-CoV-2 RBD. Crystals were obtained for the unliganded B10 Fab, which diffracted to 2.3 Å (Supplementary Table 2 ). Although no crystals were obtained for the B10 complex, analysis of the structure of the m396 parent bound to SARS-CoV-1 RBD (PDB ID 2dd8 - Supplementary Fig. 2 ) 21 reveals that the bulk of the contact surface is contributed by heavy chain interactions (517 Å 2 buried surface vs 370 Å 2 for the light chain) in which CDR H1 and H2 line one side of a cleft, whilst H3 lines the other side, into which a loop of CoV1 RBD projects (residues 484-492 SARS-CoV-1 numbering, residues 498-506 SARS-CoV-2 numbering). The m396-B10 clone contains several heavy chain CDR mutations relative to the parental m396 antibody: two in H1, four in H2, and two in H3 (Supplementary Information). Although the overall RBD fold is conserved between SARS-CoV-1 and SARS-CoV-2 ( Supplementary Fig. 2 , colored in yellow and salmon respectively), the loop bound by the m396 heavy chain cleft comprises a local divergence hotspot containing multiple substitutions: Y498Q, T499P, T501N, I503V (all SARS-CoV-2 numbering), considerably more divergent than the overall RBD. The crystal structure of the m396-B10 Fab described here lacks electron density at most of these CDR positions, indicating conformational plasticity in the unliganded state. In contrast to heavy chain, light chain residues form more limited contacts in the m396 parental complex, with CDR L1 and L3 contacting a surface with considerably greater conservation between SARS-CoV-1 and SARS-CoV-2. A total of two mutations were selected in the m396-B10 L3 region (Supplementary Sequences) which contacts the RBD in the parental m396 complex, with no mutations observed in L1 and L2 regions. To further define the epitope of m396 B10, we carried out epitope binning by BLI, which indicated competition with recombinant ACE2 (Supplementary Fig. 3A ). In addition, we generated a triple mutant within the ACE2 binding site of SARS-CoV-2 RBD (comprising T500A, N501A and Y505A, SARS-CoV-2 numbering), predicted to interfere with parental m396 binding. Mutation of this region in RBD resulted in complete loss of binding of m396-B10 (as well as for m396-C4) (Supplementary Fig. 3B ), suggesting that these variants bind to an epitope within the ACE2 binding site, as previously demonstrated for the parental m396 SARS-CoV-1 RBD interaction 11 . In addition to m396, we selected two variants of CR3022 for further characterization (clones G11 and B11). When expressed in an IgG format both antibodies displayed similar equilibrium binding constants (KD) for SARS-CoV-2 RBD as the parental CR3022 antibody: 94 nM for B11 and 131 nM for G11, respectively, compared to 99 nM for CR3022 (G11: ka 2.4x10 5 M -1 .s -1 , kd 2.2 x 10 -2 s -1 ; B11: ka 1.0x10 5 M -1 .s -1 , kd 1.3 x 10 -2 s -1 ; CR3022 parental: ka 7.2x10 4 M -1 .s -1 , kd 7.1 x 10 -3 s -1 ) (Fig. 2B , Table 1 and Supplementary Fig. 1A ). However, both the parental CR3022 IgG, as well as the G11 and B11 variants, did not detectably neutralize SARS-CoV-2 virus ( Fig. 2C and Supplementary Fig. 1E) 15 . In contrast to the m396 and CR3022 phage display selections, no enrichment was observed for the selection of the CR3014 site-directed mutagenesis library ( Fig. 2A) . In the case of the 80R selection, polyclonal ELISA indicated the selection of binders, which could also be detected by soluble ELISA in scFv format ( Supplementary Fig. 4) . Three of the selected clones, designated C9, D1 and D10 were converted into an IgG format, however binding was lost upon antibody format conversion and the clones did not display detectable neutralization activity (Fig. 2B -C and Supplementary Fig. 1E ). In addition to the site-directed mutagenesis approach described as above, we investigated light chain shuffling as a strategy for shifting the specificity of antibodies from SARS-CoV-1 towards SARS-CoV-2 17 . We utilized splice overlap extension PCR 22 to pair DNA encoding variable heavy domains of each of the four antibodies analyzed here (m396, CR3022, CR3014 and 80R) with a kappa light chain library on phage in a scFv format (Fig. 1D) . The synthetic light chain library is based on the human Vk1 framework, with diversity introduced at CDR L1, L2 and L3 position 18 . After ligation and electroporation into E. coli TG1, light chain shuffled libraries of 5 x 10 7 , 1 x 10 8 , 4 x 10 7 and 1 x 10 8 clones were obtained for m396, CR3022, CR3014 and 80R, respectively. Three rounds of phage display selection were performed using decreasing amounts of SARS-CoV-2 RBD antigen for selection (see Methods); this resulted in enrichment of binders for all of the libraries except m396, as indicated by polyclonal phage ELISA (Fig. 3A ). In the case of the CR3022 selection, binders were dominated by a single clone (designated B6) after three rounds (no additional binders were identified when screening earlier selection rounds). The CR3022-B6 variant was expressed in an IgG format in CHO cells, and further characterized by biolayer-interferometry (BLI) and for neutralization in Vero E6 cells. These analyses revealed that CR3022-B6 IgG bound to soluble recombinant SARS-CoV-2 RBD with an equilibrium binding constant (KD) of 290 nM, lower than observed for the parental CR3022 antibody (99 nM) ( Fig. 3B and Table 1 ). Intriguingly, and unlike parental CR3022, B6 was capable of neutralizing of live SARS-CoV-2 virus with an IC50 of 4.4 µg/ml (Fig. 3C) . RBD mutagenesis was used to further characterize the CR3022-B6 epitope by targeting the CR3022-RBD interface through a K396S mutation designed to disrupt the interaction (Fig. 4D In the case of the CR3014 selections, libraries became dominated by two clones (D1 and C8) after three rounds of selection. When converted into IgG (and unlike the parental CR3014 IgG, which did not detectably bind to SARS-CoV-2 RBD), both clones bound with mid-nanomolar affinity (KD of 51 nM and 61 nM respectively) ( Fig. 3B and Table 1 ). Similar to the observation for the CR3022-B6/CR3022-parental pair, only CR3014-D1 (but not CR3014-C8) was able to detectably neutralize live virus (although weakly with an IC50 >100 µg/ml) (Fig. 3C ). In the case of the 80R selections, later rounds were dominated by a set of variants with closely related CDR sequences. A representative clone (80R-A2) was expressed in an IgG format and analyzed by BLI and neutralization: this revealed that the 80R-A2 variant had acquired the capacity to bind RBD and neutralize SARS-CoV-2 with a KD of 61 nM and an IC50 of 17.8 µg/ml ( Fig. 3B -C and Table 1 ). Parental 80R has been shown to block the interaction of SARS-CoV-1 RBD with ACE2 14 . Similarly, 80R-A2 binding to SARS-CoV-2 RBD was disrupted through T500A/N501A/Y505A triple substitutions targeting the ACE2 binding site as described above (Fig. 4D surface A and Supplementary Fig. 3B ). In parallel to the affinity maturation of CR3022-B6, we crystallized this variant in a In contrast, no detectable increase of equilibrium binding affinity was observed for variants of CR3022, although two of the analysed variants displayed increased kinetic association constants for SARS-CoV-2 binding compared to the parental CR3022 antibody. However, none of the CR3022 variants generated by site-directed mutagenesis displayed detectable viral neutralization (Fig. 2C ). From the kappa light chain shuffled libraries we identified variants of antibodies CR3022, 80R and CR3014 that bound to SARS-CoV-2 RBD (no binders were obtained for m396 selections, presumably due to the presence of lambda light chain in the parental antibody). The CR3022 selections were dominated by a single clone, CR3022-B6, which bound SARS-CoV-2 with reduced affinity compared to the parental CR03022 antibody (290 nM compared to 99 nM) ( Fig. 3B and Table 1 ). Intriguingly, and unlike wild-type CR3022, CR3022-B6 effectively neutralized SARS-CoV-2 live virus with an IC50 of 4.4 µg/ml. This apparent discrepancy between affinity and neutralization potential in otherwise closely related variants was further confirmed through epitope mapping. Mutation of the SARS-CoV-2 RBD CR3022 binding site abolished binding of recombinant parental CR3022, but not of CR3022-B6 ( Supplementary Fig. 3B ). In contrast, CR3022-B6 binding was abolished by mutation of the RBD adjacent to the ACE2 binding site (L455A/F456A, Fig. 4D surface B), which did not affect binding of CR3022 wild type ( Supplementary Fig. 3B ). The suggestion that CR3022-B6 binds a different epitope to its parent was confirmed by a crystal structure of CR3022-B6 in complex with SARS-CoV-2 RBD (along with CR3014-C8 in a ternary complex), and through cryo-electron microscopy analysis of CR3022-B6 in complex with SARS-CoV-2 trimeric spike. Both structural analyses confirmed binding of CR3022-B6 in proximity to the RBD ACE2 interaction surface, and distant to the original CR3022 binding site, providing a rationale for its observed neutralization activity. The observation that a human antibody, in its wild-type and matured light chain shuffled form, can bind to two completely different epitopes is intriguing. This observation was not limited to CR3022, with similarly distinct epitopes observed among two variants of the CR3014 antibody (CR3014-C8 and CR3014-D1). Despite the absence of structural information for the parental CR3014 antibody, mutagenesis, crystallography and cryo-electron microscopy clearly highlight the considerable difference in epitope specificity for these two light chains shuffled clones. The difference in specificity also correlates well with neutralization potential: clones binding to a surface proximal to the ACE2 binding site (CR3022-B6 and CR3014-D1) We conclude that in vitro maturation provides a rapid pathway for the identification of potent antibody reagents against emerging viruses. m396, CR3022, CR3014, and 80R scFv were gene synthesized (Genscript) and cloned into the pHEN1 phagemid vector. Site-directed mutagenesis was carried out by Kunkel mutagenesis 16 . In brief, phagemid vectors were transformed into E. coli CJ236, single colonies grown in 2xYT media supplemented with 100 µg/mL ampicillin, 10 µg/mL chloramphenicol and 2% glucose until reaching an OD600nm of 0.4. Bacteria were then infected with KM13 helper phage and grown overnight at 30°C in 2xYT media supplemented with 100 µg/mL ampicillin, 10 µg/mL chloramphenicol, 50 µg/mL kanamycin and 0.25 µg/mL uridine. Phage particles were purified from the culture media using PEG/NaCl and uridine containing single-stranded DNA (dU-ssDNA) extracted using a QIAprep spin M13 kit (Qiagen). Mutagenesis was carried out by annealing degenerated oligonucleotides to the dU-ssDNA, followed by synthesis of the covalently closed circular DNA (cccDNA) with T7 DNA polymerase and T4 ligase (NEB). Finally, the cccDNA was transformed into electro-competent E. coli TG1 and bacteria titrated to determine library sizes. Bacteria were harvested from the agar plates, grown in 2xYT media supplemented with 100 µg/mL ampicillin, and 2% glucose until reaching an OD600nm of 0.4. At this point, bacteria were infected with KM13 helper phage and grown overnight at 30°C in 2xYT media supplemented with 100 µg/mL ampicillin, and 50 µg/mL kanamycin. Phage antibody libraries were purified from culture media using PEG/NaCl and stored at 4°C. DNA encoding SARS-CoV-1 VH regions was amplified by PCR (using Q5 polymerase NEB). J segments were modified as required to match the following protein sequence (GTLVTVSS). Region encoding V kappa library regions were amplified from a pHEN1 scFv library, comprising the end of the VH J segment, glycine-serine linker and VL regions. The resulting light chain shuffled library was generated by splice-overlapping extension PCR and cloned into pHEN1 in a scFv format using NcoI and NotI restriction sites. DNA was transformed into electro-competent TG1, and phage produced and purified as above. For phage display selection, we biotinylated SARS-CoV-2 RBD using a terminal Affinity maturation was carried out using off-rate selections and streptavidin magnetic beads. Selections were performed essentially as previously described 28 , with the following adjustments: phage were incubated with the biotinylated RBD for 1h, excess unbiotinylated RBD was added (100x and 350x for rounds 2 and 3) and further incubated for 2/8 h for rounds 2/3 before capture on magnetic streptavidin beads. Purified monoclonal antibodies (Fab/IgG) were buffer exchanged into PBS using 3 days at 37°C, 5% CO2. The protein was purified using the His tag as for the RBD purification. The protein was further purified on a Superose 6 gel filtration column (GE Healthcare) using an AKTA Pure FPLC instrument (GE Healthcare) to isolate the trimeric protein and remove S2 pre-fusion protein. Serial 2-fold dilutions of test monoclonal antibody were prepared in 96-well plates in octuplicate. The serial dilutions were incubated for 1 hour at 37°C with an equal volume of SARS-CoV-2 isolate containing 200 TCID50 (infectious dose). A Vero E6 suspension containing 2 x 10 4 cells was added to each well, and plates were incubated at 37°C (5% CO2). After 3 days, the plates were observed for cytopathic effect (CPE) and IC50 values were calculated from four parameter dose-response curves (GraphPad Prism). All dilution steps of antibody, virus, and cells were performed in culture media containing MEM, 2% fetal bovine serum, and 1x penicillin-streptomycin-glutamine. Cells were cultured at 37°C and 5% CO2 in growth medium containing high glucose Neutralisation assays were performed in triplicates and outliers were excluded using the modified z-score method. Percentage neutralisation of SARSpp was calculated as (1 -RLUt reatment/RLUno treatment) × 100. The 50% inhibitory concentration (IC50) titre was calculated using non-linear regression model (GraphPad Prism). Gel-filtration chromatography purified SARS-CoV-2 RBD (residues 333-528), and For sample preparation, either spike trimer alone or 1:1 Fab:monomer (molar ratio -for the CR3022-B6 or CR3014-D1 datasets) was incubated at room temperature for 1 h before applying to holey gold grids and freezing. 3.5 µl of each sample was applied to and blob particle picking were performed in cryoSPARC 35 . Extracted particles were subjected to multiple rounds of 2D classification and ab initio reconstruction in cryoSPARC before their locations were exported to Relion 3.0 36 . Motion correction and CTF estimation was then implemented in Relion 3.0 and particles were reextracted and again subjected to 2D classification before 3D auto-refinement and Bayesian polishing. 3D classification was then used to sort the particles based on whether density (attributed to Fab) was present above on of the RBDs. The final Fab bound trimer particles were then imported back to cryoSPARC for NU-3D refinement. Supplementary Fig. 6 provides a flowchart to describe this workflow along with FSC curves. Supplementary Table 3 provides a summary of the data collection and refinement statistics. The authors declare no competing financial interest. Table 1 Table 1 CR3022-H1 I30 DWY Y, D, I, N, F, V T31 DMY Y 80R-H2 Y52A KMT Y, A, D, S D53 S55 N56 DMY Y, A, D, S, N, T 80R-H3 D95 KMT Y, A, D, S R96 VRV R, H, Q, K, D, E, G, N, S S97 DMY Y Human Coronavirus: Host-Pathogen Interaction SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model Structural basis of a shared antibody response to SARS-CoV Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes Isolation of a human monoclonal antibody specific for the receptor binding domain of SARS-CoV-2 using a competitive phage biopanning strategy The Nucleocapsid Protein of SARS-CoV-2: a Target for Vaccine Development A pneumonia outbreak associated with a new coronavirus of probable bat origin Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV Generation of human single domain antibody repertoires by Kunkel mutagenesis Light chain shuffling of a high affinity antibody results in a drift in epitope recognition Structural reconstruction of protein ancestry General strategy for the generation of human antibody variable domains with increased aggregation resistance Structural basis of neutralization by a human anti-severe acute respiratory syndrome spike protein antibody, 80R Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody A general method of in vitro preparation and specific mutagenesis of DNA fragments: study of protein and DNA interactions RSV neutralization by palivizumab, but not by monoclonal antibodies targeting other epitopes, is augmented by Fc gamma receptors Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG The extent of affinity maturation differs between the memory and antibody-forming cell compartments in the primary immune response Memory B cells, but not long-lived plasma cells, possess antigen specificities for viral escape mutants Selection of human antibody fragments by phage display Computational analysis of off-rate selection experiments to optimize affinity maturation by directed evolution An introduction to data reduction: space-group determination, scaling and intensity statistics How good are my data and what is the resolution? Overview of the CCP4 suite and current developments Solving structures of protein complexes by molecular replacement with Phaser Gctf: Real-time CTF determination and correction cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination RELION: implementation of a Bayesian approach to cryo-EM structure determination We thank the UTS Biologics Innovation Facility for help on SARS-CoV-2 spike protein production, and Pamela J.